Deutsche Bank Ag\ Kempharm, Inc Transaction History

Deutsche Bank Ag\

$262 Billion
Q2 2025

A detailed history of Deutsche Bank Ag\ transactions in Kempharm, Inc stock. As of the latest transaction made, Deutsche Bank Ag\ holds 38,470 shares of KMPH stock, worth $190,041. This represents 0.0% of its overall portfolio holdings.

Number of Shares

38,470

Previous 45,681 15.79%

Holding current value

$190,041

Previous $225,000 15.56%

% of portfolio

0.0%

Previous 0.0%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	N/A	-7,211 Reduced 15.79%	38,470 $190,000
Q1 2025 May 09, 2025	SELL	N/A	-5,225 Reduced 10.26%	45,681 $225,000
Q4 2024 Jun 30, 2025	BUY	N/A	5,225 Added 11.44%	50,906 $251,000
Q4 2024 Feb 14, 2025	BUY	N/A	10,306 Added 25.38%	50,906 $251,000
Q3 2024 Jun 26, 2025	SELL	N/A	-5,081 Reduced 11.12%	40,600 $200,000
Q3 2024 Nov 13, 2024	BUY	N/A	10,131 Added 33.25%	40,600 $200,000
Q2 2024 Jun 12, 2025	SELL	N/A	-15,212 Reduced 33.3%	30,469 $150,000
Q2 2024 Aug 14, 2024	BUY	N/A	12,846 Added 72.89%	30,469 $150,000
Q1 2024 Jun 02, 2025	SELL	N/A	-28,058 Reduced 61.42%	17,623 $87,000
Q1 2024 May 15, 2024	BUY	N/A	870 Added 5.19%	17,623 $87,000
Q4 2023 Feb 14, 2024	BUY	N/A	701 Added 4.37%	16,753 $82,000
Q3 2023 Nov 09, 2023	BUY	N/A	16,052 New	16,052 $79,000
Q2 2022 Aug 11, 2022	SELL	$4.02 - $5.21 $62,800 - $81,390	-15,622 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$5.0 - $9.26 $8,560 - $15,853	-1,712 Reduced 9.88%	15,622 $79,000
Q4 2021 Feb 11, 2022	BUY	$7.6 - $10.26 $6,840 - $9,234	900 Added 5.48%	17,334 $151,000
Q3 2021 Nov 04, 2021	SELL	$8.72 - $13.31 $22,262 - $33,980	-2,553 Reduced 13.45%	16,434 $153,000
Q2 2021 Aug 11, 2021	BUY	$8.52 - $15.47 $161,769 - $293,728	18,987 New	18,987 $244,000

Others Institutions Holding KMPH

# of Institutions

123

Shares Held

30M

Call Options Held

186K

Put Options Held

597K

View Full List

About KEMPHARM, INC

Ticker KMPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,493,600
Market Cap $170M
Description
KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds t...

More about KMPH

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account